NOTA-octreotide | ligand | [18F]AlF-NOTA-octreotide | PET/CT imaging agent

MedKoo Cat#: 125680 | Name: NOTA-octreotide

Description:

WARNING: This product is for research use only, not for human or veterinary use.

NOTA-octreotide is a ligand for making [18F]AlF-NOTA-octreotide, which is a PET/CT imaging agent for somatostatin receptor imaging in neuroendocrine tumor patients.

Chemical Structure

NOTA-octreotide

CAS#N/A

Theoretical Analysis

MedKoo Cat#: 125680

Name: NOTA-octreotide

CAS#: N/A

Chemical Formula: C61H85N13O15S2

Exact Mass: 1303.5700

Molecular Weight: 1304.55

Elemental Analysis: C, 56.16; H, 6.57; N, 13.96; O, 18.40; S, 4.92

Price and Availability

Size	Price	Availability
5mg	USD 1,650.00	2 Weeks
10mg	USD 2,950.00	2 Weeks
100mg	USD 6,950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

NOTA-octreotide; NOTA octreotide; NOTAoctreotide

IUPAC/Chemical Name

2,2'-(7-(2-(((R)-1-(((4R,7S,10S,13R,16S,19R)-13-((1H-indol-3-yl)methyl)-10-(4-aminobutyl)-16-benzyl-4-(((2S,3R)-1,3-dihydroxybutan-2-yl)carbamoyl)-7-((S)-1-hydroxyethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-19-yl)amino)-1-oxo-3-phenylpropan-2-yl)amino)-2-oxoethyl)-1,4,7-triazonane-1,4-diyl)diacetic acid

InChi Key

VTMXEQNYVKRXNE-NJCTUWBNSA-N

InChi Code

InChI=1S/C61H85N13O15S2/c1-37(76)48(34-75)68-60(88)50-36-91-90-35-49(69-56(84)45(27-39-13-5-3-6-14-39)64-51(78)31-72-21-23-73(32-52(79)80)25-26-74(24-22-72)33-53(81)82)59(87)66-46(28-40-15-7-4-8-16-40)57(85)67-47(29-41-30-63-43-18-10-9-17-42(41)43)58(86)65-44(19-11-12-20-62)55(83)71-54(38(2)77)61(89)70-50/h3-10,13-18,30,37-38,44-50,54,63,75-77H,11-12,19-29,31-36,62H2,1-2H3,(H,64,78)(H,65,86)(H,66,87)(H,67,85)(H,68,88)(H,69,84)(H,70,89)(H,71,83)(H,79,80)(H,81,82)/t37-,38+,44+,45-,46+,47-,48+,49+,50+,54+/m1/s1

SMILES Code

O=C(N[C@H](CC1=CC=CC=C1)C(N[C@@H]2C(N[C@@H](CC3=CC=CC=C3)C(N[C@@H](C(N[C@@H](CCCCN)C(N[C@@H]([C@H](C)O)C(N[C@@H](CSSC2)C(N[C@H]([C@H](O)C)CO)=O)=O)=O)=O)CC4=CNC5=C4C=CC=C5)=O)=O)=O)CN6CCN(CC(O)=O)CCN(CC(O)=O)CC6

Appearance

To be determined

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,304.55 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Tshibangu T, Cawthorne C, Serdons K, Pauwels E, Gsell W, Bormans G, Deroose CM, Cleeren F. Automated GMP compliant production of [¹⁸F]AlF-NOTA- octreotide. EJNMMI Radiopharm Chem. 2020 Jan 29;5(1):4. doi: 10.1186/s41181-019-0084-1. PMID: 31997090; PMCID: PMC6989705. 2: Long T, Hou J, Yang N, Zhou M, Li Y, Li J, Tang Y, Chen D, Hu S. Utility of 18F-AlF-NOTA-Octreotide PET/CT in the Localization of Tumor-Induced Osteomalacia. J Clin Endocrinol Metab. 2021 Sep 27;106(10):e4202-e4209. doi: 10.1210/clinem/dgab258. PMID: 33864458. 3: Haeger A, Soza-Ried C, Kramer V, Hurtado de Mendoza A, Eppard E, Emmanuel N, Wettlin J, Amaral H, Fernández R. Al[¹⁸F]F-NOTA-Octreotide Is Comparable to [⁶⁸Ga]Ga-DOTA-TATE for PET/CT Imaging of Neuroendocrine Tumours in the Latin-American Population. Cancers (Basel). 2023 Jan 10;15(2):439. doi: 10.3390/cancers15020439. PMID: 36672388; PMCID: PMC9856643. 4: Ahenkorah S, Cawthorne C, Murce E, Deroose CM, Cardinaels T, Seimbille Y, Bormans G, Ooms M, Cleeren F. Direct comparison of [¹⁸F]AlF-NOTA-JR11 and [¹⁸F]AlF-NOTA-octreotide for PET imaging of neuroendocrine tumors: Antagonist versus agonist. Nucl Med Biol. 2023 Mar-Apr;118-119:108338. doi: 10.1016/j.nucmedbio.2023.108338. Epub 2023 Mar 29. PMID: 37018875. 5: Laverman P, D'Souza CA, Eek A, McBride WJ, Sharkey RM, Oyen WJ, Goldenberg DM, Boerman OC. Optimized labeling of NOTA-conjugated octreotide with F-18. Tumour Biol. 2012 Apr;33(2):427-34. doi: 10.1007/s13277-011-0250-x. Epub 2011 Oct 19. PMID: 22009690; PMCID: PMC3296034. 6: Hou J, Long T, Yang N, Chen D, Zeng S, Zheng K, Liao G, Hu S. Biodistribution of ¹⁸F-AlF-NOTA-octreotide in Different Organs and Characterization of Uptake in Neuroendocrine Neoplasms. Mol Imaging Biol. 2021 Dec;23(6):827-835. doi: 10.1007/s11307-021-01628-7. Epub 2021 Jul 6. PMID: 34231107. 7: Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K, Dekervel J, Van Cutsem E, Verslype C, Van Laere K, Bormans G, Deroose CM. [¹⁸F]AlF-NOTA- octreotide PET imaging: biodistribution, dosimetry and first comparison with [⁶⁸Ga]Ga-DOTATATE in neuroendocrine tumour patients. Eur J Nucl Med Mol Imaging. 2020 Dec;47(13):3033-3046. doi: 10.1007/s00259-020-04918-4. Epub 2020 Jul 2. PMID: 32617641. 8: Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K, Boeckxstaens L, Dekervel J, Vandamme T, Lybaert W, den Broeck BV, Laenen A, Clement PM, Geboes K, Cutsem EV, Stroobants S, Verslype C, Bormans G, Deroose CM. ¹⁸F-AlF-NOTA-Octreotide Outperforms ⁶⁸Ga-DOTATATE/NOC PET in Neuroendocrine Tumor Patients: Results from a Prospective, Multicenter Study. J Nucl Med. 2023 Apr;64(4):632-638. doi: 10.2967/jnumed.122.264563. Epub 2022 Oct 20. PMID: 36265911. 9: Laverman P, McBride WJ, Sharkey RM, Eek A, Joosten L, Oyen WJ, Goldenberg DM, Boerman OC. A novel facile method of labeling octreotide with (18)F-fluorine. J Nucl Med. 2010 Mar;51(3):454-61. doi: 10.2967/jnumed.109.066902. Epub 2010 Feb 11. PMID: 20150268; PMCID: PMC2908260. 10: Boeckxstaens L, Pauwels E, Vandecaveye V, Deckers W, Cleeren F, Dekervel J, Vandamme T, Serdons K, Koole M, Bormans G, Laenen A, Clement PM, Geboes K, Van Cutsem E, Nackaerts K, Stroobants S, Verslype C, Van Laere K, Deroose CM. Prospective comparison of [¹⁸F]AlF-NOTA-octreotide PET/MRI to [⁶⁸Ga]Ga-DOTATATE PET/CT in neuroendocrine tumor patients. EJNMMI Res. 2023 Jun 1;13(1):53. doi: 10.1186/s13550-023-01003-3. PMID: 37261615; PMCID: PMC10235004.